We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+12.99%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$725M
AUM Growth
+$66.7M
Cap. Flow
+$16.4M
Cap. Flow %
2.26%
Top 10 Hldgs %
41.88%
Holding
145
New
38
Increased
32
Reduced
27
Closed
36

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$25.1M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$19.4M
3
AMGN icon
Amgen
AMGN
+$17.7M
4
BLUE
bluebird bio
BLUE
+$12.8M
5
VTRS icon
Viatris
VTRS
+$11M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$28.5M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.3M
3
SHPG
Shire pic
SHPG
+$11.3M
4
FOLD
Amicus Therapeutics
FOLD
+$9.93M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.8M

Sector Composition

Rank Sector Weight
1 Healthcare 72.21%
2 Technology 6.12%
3 Financials 1.97%
4 Industrials 1.58%
5 Consumer Discretionary 1.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRCA icon
76
Verrica Pharmaceuticals
VRCA
$89.7M
$2.48M 0.34%
+12,580
New +$2.46M
APTX
77
DELISTED
Aptinyx Inc. Common Stock
APTX
$2.48M 0.34%
+102,474
New +$2.19M
APLS
78
DELISTED
Apellis Pharmaceuticals
APLS
$2.44M 0.34%
+110,803
New +$2.55M
MRVL icon
79
Marvell Technology
MRVL
$168B
$2.35M 0.32%
+109,842
New +$2.34M
SEDG icon
80
SolarEdge
SEDG
$2.51B
$2.34M 0.32%
48,948
+31,758
+185% +$1.76M
KRNT icon
81
Kornit Digital
KRNT
$705M
$2.33M 0.32%
+130,831
New +$2.07M
NEOS
82
DELISTED
Neos Therapeutics, Inc
NEOS
$2.2M 0.3%
352,142
+31,450
+10% +$234K
CTMX icon
83
CytomX Therapeutics
CTMX
$675M
$1.9M 0.26%
83,142
-96,858
-54% -$2.47M
VTGN icon
84
VistaGen Therapeutics
VTGN
$9.89M
$1.88M 0.26%
45,730
+4,155
+10% +$144K
TBIO
85
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$1.65M 0.23%
+130,000
New +$1.57M
GILT icon
86
Gilat Satellite Networks
GILT
$834M
$1.5M 0.21%
163,367
+51,721
+46% +$434K
PTLA
87
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$1.39M 0.19%
+120,000
New +$4.59M
DK icon
88
Delek US
DK
$4.16B
$1.23M 0.17%
24,533
-97,751
-80% -$4.86M
ZYME icon
89
Zymeworks
ZYME
$1.61B
$1.09M 0.15%
+73,800
New +$1.14M
RDCM icon
90
Radcom
RDCM
$171M
$1.04M 0.14%
52,760
-13,000
-20% -$253K
AAP icon
91
Advance Auto Parts
AAP
$3.35B
$724K 0.1%
5,336
– –
MRTX
92
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$707K 0.1%
+14,335
New +$541K
NGNE icon
93
Neurogene
NGNE
$656M
$683K 0.09%
12,881
+9,104
+241% +$2.37M
RCKT icon
94
Rocket Pharmaceuticals
RCKT
$340M
$677K 0.09%
34,475
-267,800
-89% -$5.07M
TCDA
95
DELISTED
Tricida, Inc. Common Stock
TCDA
$610K 0.08%
+20,410
New +$570K
BMRN icon
96
BioMarin Pharmaceuticals
BMRN
$11.6B
$589K 0.08%
+6,250
New +$547K
TMX
97
DELISTED
Terminix Global Holdings, Inc.
TMX
$565K 0.08%
14,184
– –
UNH icon
98
UnitedHealth
UNH
$376B
$491K 0.07%
2,000
– –
AUDC icon
99
AudioCodes
AUDC
$244M
$461K 0.06%
+59,226
New +$429K
RDWR icon
100
Radware
RDWR
$1.1B
$443K 0.06%
17,527
-703
-4% -$16.3K
2 3
4
5 6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2018 Portfolio in Review

As of Q2 2018, Sphera Funds Management held 145 positions worth $725M, up 10% from $659M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Sphera Funds Management's Q2 2018 filing shows 38 new, 32 increased, 27 reduced and 36 closed positions. Its largest new stake was Gilead Sciences: 355,000 shares worth $25.1M. The largest sale was Celgene Corp, an estimated $28.5M.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, down from 75% a quarter earlier, followed by Technology and Financials.

  • Sphera Funds Management's largest Q2 2018 buy was Gilead Sciences: 355,000 shares worth $25.1M.
  • Sphera Funds Management added most to Viatris in Q2 2018, an estimated $11M increase.
  • Sphera Funds Management's biggest Q2 2018 reduction was Shire pic, cutting an estimated $11.3M.
  • Sphera Funds Management fully exited Celgene Corp in Q2 2018, selling an estimated $28.5M.
  • Sphera Funds Management's ten largest holdings make up 42% of its $725M portfolio in Q2 2018.
  • Sphera Funds Management opened 38 new positions and closed 36 in Q2 2018.
  • Sphera Funds Management's portfolio value rose 10% quarter-over-quarter to $725M.

Based on Sphera Funds Management's 13F filing for Q2 2018, filed 13 Aug 2018.